UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

The place beyond the trees: renewed excavations of the Middle Stone Age deposits at Olieboomspoort in the Waterberg Mountains of the South African Savanna Biome

Archaeological and anthropological sciences, 2021-07, Vol.13 (7), Article 116

2021

Link zum Volltext

Verfügbarkeit prüfen

Raman signatures of the modern pigment (Zn,Cd)S1−xSex and glass matrix of a red bead from Magoro Hill, an archaeological site in Limpopo Province, South Africa, recalibrate the settlement chronology

Journal of molecular structure, 2012-09, Vol.1023, p.123-127

2012

Link zum Volltext

Verfügbarkeit prüfen

Unravelling the glass trade bead sequence from Magoro Hill, South Africa: separating pre-seventeenth-century Asian imports from later European counterparts

Heritage science, 2016-12, Vol.4 (1), p.1, Article 43

2016

Link zum Volltext

Verfügbarkeit prüfen

Towards refining the classification of glass trade beads imported into Southern Africa from the 8th to the 16th century AD

Journal of cultural heritage, 2016-05, Vol.19, p.435-444

2016

Link zum Volltext

Verfügbarkeit prüfen

Raman signatures of the modern pigment (Zn,Cd)S1axSex and glass matrix of a red bead from Magoro Hill, an archaeological site in Limpopo Province, South Africa, recalibrate the settlement chronology

Journal of molecular structure, 2012-09, Vol.1023, p.123-127

2012

Link zum Volltext

Verfügbarkeit prüfen

Rocks of Potency: Engravings and Cupules from the Dovedale Ward, Southern Tuli Block, Botswana [with Comment]

South African archaeological bulletin, 2004-06, Vol.59 (179), p.1-11

2004

Link zum Volltext

Verfügbarkeit prüfen

Middle Stone Age Lithic Point Experimentation for Macro-Fracture and Residue Analysis: The Process and Preliminary Results with Reference to Sibudu Cave Points: Sibudu Cave

South African journal of science, 2004-03, Vol.100 (3-4), p.159-159

2004

Link zum Volltext

Verfügbarkeit prüfen

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Journal of Virology, 2006-05, Vol.80 (10), p.4909-4920

2006

Link zum Volltext

Verfügbarkeit prüfen

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

The New England journal of medicine, 2008-10, Vol.359 (14), p.1429-1441

2008

Link zum Volltext

Verfügbarkeit prüfen

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

The New England journal of medicine, 2008-10, Vol.359 (14), p.1442-1455

2008

Link zum Volltext

Verfügbarkeit prüfen

Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc

Antiviral chemistry & chemotherapy, 2021, Vol.29, p.20402066211025156-20402066211025156

2021

Link zum Volltext

Verfügbarkeit prüfen

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens

Antiviral chemistry & chemotherapy, 2021, Vol.29, p.204020662110303-20402066211030380

2021

Link zum Volltext

Verfügbarkeit prüfen

The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF‐4878691)

Clinical pharmacology and therapeutics, 2011-06, Vol.89 (6), p.821-829

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

Nature medicine, 2005-11, Vol.11 (11), p.1170-1172

2005

Link zum Volltext

Verfügbarkeit prüfen

CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection

Antiviral Chemistry and Chemotherapy, 2005-12, Vol.16 (6), p.339-354

2005

Link zum Volltext

Verfügbarkeit prüfen

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials

PloS one, 2018-12, Vol.13 (12), p.e0204099

2018

Link zum Volltext

Verfügbarkeit prüfen

An exploratory survey measuring stigma and discrimination experienced by people living with HIV/AIDS in South Africa: the People Living with HIV Stigma Index

BMC public health, 2014-01, Vol.14 (1), p.80-80, Article 80

2014

Link zum Volltext

Verfügbarkeit prüfen

A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc

Clinical pharmacology and therapeutics, 2005-11, Vol.78 (5), p.508-519

2005

Link zum Volltext

Verfügbarkeit prüfen

Hepatic safety and tolerability in the maraviroc clinical development program

AIDS (London), 2010-11, Vol.24 (17), p.2743-2750

2010

Link zum Volltext

Verfügbarkeit prüfen

Eating Disorders in Adolescence: Anorexia and Bulimia Nervosa

Steinhausen, Hans-Christoph

1, 2020

Link zum Volltext

Verfügbarkeit prüfen

Nutritional status of HIV-1 seropositive patients in the Free State Province of South Africa : Anthropometric and dietary profile

European journal of clinical nutrition, 1999-03, Vol.53 (3), p.165-173

1999

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic/ pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV‐positive patients

British journal of clinical pharmacology, 2008-04, Vol.65 (s1), p.86-94

2008

Link zum Volltext

Verfügbarkeit prüfen

968 GENOTYPIC CHARACTERISATION OF HCV NS5B FOLLOWING 8-DAY MONOTHERAPY WITH THE POLYMERASE INHIBITOR PF-00868554 IN HCV-INFECTED SUBJECTS

Journal of hepatology, 2009, Vol.50, p.S351-S351

2009

Link zum Volltext

Verfügbarkeit prüfen

Baseline CD4+ T―cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment―experienced patients

Antiviral therapy, 2011-01, Vol.16 (3), p.395-404

2011

Link zum Volltext

Verfügbarkeit prüfen

Lersivirine: a new NNRTI active across HIV‐1 subtypes with a unique resistance profile

Journal of the International AIDS Society, 2010-11, Vol.13 (S4), p.O49-O49

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(47)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Humans
(32)
Life Sciences & Biomedicine
(32)
Infectious Diseases
(18)
Biological And Medical Sciences
(17)
Medical Sciences
(17)
Aids/hiv
(14)
Male
(14)
Female
(13)
Viral Diseases
(13)
Adult
(12)
Hiv Infections - Drug Therapy
(12)
Human Viral Diseases
(12)
Middle Aged
(12)
Animals
(10)
Ccr5 Receptor Antagonists
(9)
Hiv-1 - Genetics
(9)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(9)
General & Internal Medicine
(8)
Hiv
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The place beyond the trees: renewed excavations of the Middle Stone Age deposits at Olieboomspoort in the Waterberg Mountains of the South African Savanna Biome

Raman signatures of the modern pigment (Zn,Cd)S1−xSex and glass matrix of a red bead from Magoro Hill, an archaeological site in Limpopo Province, South Africa, recalibrate the settlement chronology

Unravelling the glass trade bead sequence from Magoro Hill, South Africa: separating pre-seventeenth-century Asian imports from later European counterparts

Towards refining the classification of glass trade beads imported into Southern Africa from the 8th to the 16th century AD

Raman signatures of the modern pigment (Zn,Cd)S1axSex and glass matrix of a red bead from Magoro Hill, an archaeological site in Limpopo Province, South Africa, recalibrate the settlement chronology

Rocks of Potency: Engravings and Cupules from the Dovedale Ward, Southern Tuli Block, Botswana [with Comment]

Middle Stone Age Lithic Point Experimentation for Macro-Fracture and Residue Analysis: The Process and Preliminary Results with Reference to Sibudu Cave Points: Sibudu Cave

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens

The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF‐4878691)

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials

An exploratory survey measuring stigma and discrimination experienced by people living with HIV/AIDS in South Africa: the People Living with HIV Stigma Index

A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc

Hepatic safety and tolerability in the maraviroc clinical development program

Eating Disorders in Adolescence: Anorexia and Bulimia Nervosa

Nutritional status of HIV-1 seropositive patients in the Free State Province of South Africa : Anthropometric and dietary profile

Population pharmacokinetic/ pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV‐positive patients

968 GENOTYPIC CHARACTERISATION OF HCV NS5B FOLLOWING 8-DAY MONOTHERAPY WITH THE POLYMERASE INHIBITOR PF-00868554 IN HCV-INFECTED SUBJECTS

Baseline CD4+ T―cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment―experienced patients

Lersivirine: a new NNRTI active across HIV‐1 subtypes with a unique resistance profile

Suchergebnisse filtern